{"id":32349,"date":"2025-04-24T15:13:38","date_gmt":"2025-04-24T07:13:38","guid":{"rendered":"https:\/\/flcube.com\/?p=32349"},"modified":"2025-04-24T17:18:09","modified_gmt":"2025-04-24T09:18:09","slug":"baheal-partners-with-jiluntai-for-commercialization-of-technetium-99m-labeled-imaging-agent","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32349","title":{"rendered":"Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent"},"content":{"rendered":"\n

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015<\/a>) has entered into a commercialization partnership with Beijing Jiluntai Pharmaceutical Co., Ltd (Radio technology). Under the agreement, Baheal secures the rights to commercialize Jiluntai\u2019s Category 1 nuclear pharmaceutical drug, Technetium-99m-labeled hydrazinylnicotinamide-polyethylene glycol-bicyclic RGD peptide, in mainland China.<\/p>\n\n\n\n

Partnership Terms and Financials<\/strong>
Baheal will pay Jiluntai a licensing fee of up to RMB 50 million (USD 6.9 million) in installments. The agreement includes a refund clause: if the product fails to obtain marketing approval from the National Medical Products Administration (NMPA) by June 30, 2026, Baheal will receive a refund of the licensing fee plus any accrued interest.<\/p>\n\n\n\n

Product Innovation and Clinical Progress<\/strong>
Jiluntai\u2019s Technetium-99m-labeled hydrazinylnicotinamide-polyethylene glycol-bicyclic RGD peptide is recognized as the world\u2019s first broad-spectrum tumor imaging agent for SPECT imaging. The drug has demonstrated significant promise in its Phase III clinical trials, achieving both primary and secondary endpoints. This innovation underscores the potential for advancing tumor detection and diagnosis through advanced imaging technologies.-Fineline Info & Tech<\/a><\/p>\n\n\n\n